DiaMedica Therapeutics Inc.
DMAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $18 | $0 | $0 | $11 |
| Gross Profit | -$18 | $0 | $0 | -$11 |
| % Margin | – | – | – | – |
| R&D Expenses | $6,437 | $5,822 | $5,656 | $6,470 |
| G&A Expenses | $0 | $2,185 | $2,443 | $0 |
| SG&A Expenses | $2,578 | $2,185 | $2,488 | $1,938 |
| Sales & Mktg Exp. | $0 | $0 | $45 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9,015 | $8,007 | $8,144 | $8,408 |
| Operating Income | -$9,033 | -$8,007 | -$8,144 | -$8,419 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $419 | $314 | $443 | $528 |
| Pre-Tax Income | -$8,614 | -$7,693 | -$7,701 | -$7,891 |
| Tax Expense | $6 | $6 | $6 | $9 |
| Net Income | -$8,620 | -$7,699 | -$7,707 | -$7,900 |
| % Margin | – | – | – | – |
| EPS | -0.17 | -0.18 | -0.18 | -0.18 |
| % Growth | 5.6% | 0% | 0% | – |
| EPS Diluted | -0.17 | -0.18 | -0.18 | -0.18 |
| Weighted Avg Shares Out | 49,630 | 42,958 | 42,844 | 42,819 |
| Weighted Avg Shares Out Dil | 49,630 | 42,958 | 42,844 | 42,819 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $18 | $3 | $11 | $11 |
| EBITDA | -$8,596 | -$8,004 | -$8,133 | -$7,880 |
| % Margin | – | – | – | – |